Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Becaplermin
Therapeutic Area : Podiatry
Study Phase : Approved FDF
Recipient : SMITH & NEPHEW INC
Deal Size : Undisclosed
Deal Type : Acquisition
Lynch Regenerative Acquires REGRANEX® Gel for Soft Tissue Regeneration
Details : Under the acquisition, Lynch holds the exclusive rights to Regranex (becaplermin) gel and recombinant purified platelet-derived growth factor (PDGF). It is being indicated for diabetic foot ulcer.
Product Name : Regranex
Product Type : Peptide
Upfront Cash : Undisclosed
March 31, 2025
Lead Product(s) : Becaplermin
Therapeutic Area : Podiatry
Highest Development Status : Approved FDF
Recipient : SMITH & NEPHEW INC
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Recombinant Human PDGF-BB
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Recipient : Alexander Hawkins
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating an RhPDGF-BB-enhanced Collagen Plug for Perianal Fistula Healing
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Recombinant Human PDGF-BB
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Recipient : Alexander Hawkins
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Recombinant Human PDGF-BB
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Recipient : Vanderbilt University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluating rhPDGF-BB-Enhanced Wound Matrix for Head and Neck Reconstruction
Details : Undisclosed
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 09, 2024
Lead Product(s) : Recombinant Human PDGF-BB
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Recipient : Vanderbilt University Medical Center
Deal Size : Inapplicable
Deal Type : Inapplicable